Objective: To study the prevalence and severity of possible drug-drug interactions in the department of pediatrics. Methods:Case records of the in-patients of the pediatrics department from the medical records department were included and the records of the ambulatory patients were excluded from the study. All the collected cases were subjected to check for the drug-drug interactions by using the software micromedex 2.0 and the interactions were categorized based on the severity into minor, moderate and major.Results: A total of 142 cases were screened for possible drug-drug interactions (DDIs) and among them 76 cases were observed to be with possible DDIs. The prevalence was found to be 53.5% in this study. Majority of the cases with possible DDIs were observed to be in females. Results of the age wise categorization revealed that majority of the possible DDIS were observed in children (2-12 y) followed by the infants (1 mo-2 y). The drug combinations amikacin+ampicillin, paracetamol+phenytoin and ofloxacin+ondansetron were found to be the frequently observed possible DDIs of minor, moderate and major severities respectively. Conclusion:Majority of the possible DDIs were of moderate severity followed by major. Clinical pharmacists should take the responsibility in assisting the pediatricians for screening the possible DDIs in the prescriptions there by preventing them and providing a better pharmaceutical care for the pediatric population.
Nocturnal Enuresis (NE) is the involuntary passing of urine whileasleep after the age at which bladder control would normally be prevised. NE has hassled humans for hundreds of years. It has been recognized since the time of Papyrus Ebers, 1550 B.C. Various potions were prepared by using different plants, animals or organs in some of the early treatment modalities. A number of medications have been used to treat nocturnal enuresis where, Imipramine and Desmopressin acetate were found to be efficacious. Besides, some credit has also been given to Oxybutynin. Because of the high relapse rates recited after short-term therapy with pharmacotherapeutic agents, pharmacological treatment for NE is best considered as management therapy rather than a cure. In this review article, we have mainly focused on the treatment and management of nocturnal enuresis by reviewing various treatment modalities along with behavioural modifications, bladder retention training, hypnotherapy, psychotherapy and combination therapy.
Background To compare the efficacy of brinzolamide 1%/timolol 0.5% fixed drug combination (BTFC) with brinzolamide 1%/brimonidine 0.2% fixed drug combination (BBFC) among the patients with primary open-angle glaucoma (POAG). Results The treatment with BTFC in the Group A subjects showed a significant decrease in the intraocular pressure (p = 0.0355*) and a significant increase in the central corneal thickness (p = 0.0087*). Similarly, in the Group B subjects, the treatment with BBFC showed a significant decrease in the intraocular pressure (p = 0.0327*) and a significant increase in the central corneal thickness (p = 0.0227*). In the process of comparing both the fixed drug combinations, there was no significant difference observed in the aspect of efficacy between both the groups in the decrease of intraocular pressure (p = 0.7100) and in the increase of central corneal thickness (p = 0.4077). Conclusion Both the fixed drug combinations almost showed a similar efficacy in treating the respective groups, and there is no significant difference observed in the aspect of efficacy between both the fixed drug combinations in decreasing the intraocular pressure and in increasing the central corneal thickness.
To study the pattern of possible drug-drug interactions among different specialties at an Indian tertiary care teaching hospital. The present study was a retrospective study where the inpatient case records of psychiatry, chest & tuberculosis, gynecology & obstetrics and orthopedics were included. By using the software Micromedex 2.0, all the collected cases were screened for possible DDIs and the severity of the interactions was classified into minor, moderate and major. A total of 205 cases were screened for possible DDIs and about 120 (58.5%) cases were observed to be with possible DDIs. Among all the departments, moderate polypharmacy was observed to be more in the prescriptions (41.7%).A total of 314 possible DDIs were observed and most of the possible DDIs were of moderate severity (64.1%). Majority of the possible DDIs were found in the department of gynecology & obstetrics (42.4%) followed by the psychiatry department (29.6%). In order to reduce the DDIs, rationale prescriptions must be prescribed by considering the risk benefit ratio. Clinical pharmacists should take the responsibility in assisting all the prescribers for screening the possible DDIs in the prescriptions there by preventing them and providing a better pharmaceutical care in various specialties.
Huntington’s disease (HD) is a rare autosomal dominant, fatal neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioural disruption, psychiatric disturbances and dementia. This condition is characterized by progressive degeneration of neurons within the basal ganglia, primarily the caudate and the putamen. As the disease progresses, neuronal losses occur in the white matter, cerebral cortex and thalamus. In this article, the authors reviewed the genetic aspects, etiological factors, stages of the disease condition along with the signs and symptoms, various diagnostic procedures besides with the pharmacological and non-pharmacological management of the Huntington’s disease. This disease is inherited within the families, and the pathophysiology of Huntington disease is restricted to the brain, where degeneration begins initially in the striatum, spreads to the cortex and eventually appears throughout the brain.The pathogenesis of this disease is still unrevealed, and there is no treatment available for the cure of the disease. There were many drugs of choices available for symptomatic treatment aiming to improve the quality of life in the patient. The non-pharmacological therapy for managing Huntington’s disease includes physiotherapy, speech therapy and psychotherapy.At a therapeutic setting, all the needs of the patients are to be addressed as the advancement in the development of new therapeutic agents are paving the way for the better outcomes in the management of Huntington’s disease and thereby promising better healthcare for these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.